Molly Moore Jeffery, PhD, MPP

Previous studies have found modest uptake of biosimilars in both commercial and Medicare populations. This study finds that the uptake varies between the rural and urban provider settings.

After the CDC guidelines’ release, total opioid marketing spending and encounters per physician decreased, but spending per encounter subsequently increased.

Although previous work has found lower costs for biosimilar filgrastim compared with reference filgrastim, this study found that site of care can change this calculus, reducing savings.